share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/08/28 04:35

Moomoo AI 已提取核心信息

Nukkleus has received multiple non-compliance notifications from Nasdaq, including the latest on August 22, 2024, regarding failure to file Q2 2024 Form 10-Q. The company faces three additional listing compliance issues: trading below $1.00 per share, market value of publicly held shares below $15 million, and market value of listed securities below $50 million.The company must submit a compliance plan to Nasdaq by October 21, 2024. If accepted, Nasdaq may grant an extension until February 17, 2025, to regain compliance. For the bid price issue, the company has until November 4, 2024, while the market value requirements must be met by November 12, 2024.While working to file the Form 10-Q and address these compliance issues, Nukkleus's common stock continues to trade on the Nasdaq Global Market. However, there is no guarantee the company will regain compliance within prescribed timeframes or receive additional extensions.
Nukkleus has received multiple non-compliance notifications from Nasdaq, including the latest on August 22, 2024, regarding failure to file Q2 2024 Form 10-Q. The company faces three additional listing compliance issues: trading below $1.00 per share, market value of publicly held shares below $15 million, and market value of listed securities below $50 million.The company must submit a compliance plan to Nasdaq by October 21, 2024. If accepted, Nasdaq may grant an extension until February 17, 2025, to regain compliance. For the bid price issue, the company has until November 4, 2024, while the market value requirements must be met by November 12, 2024.While working to file the Form 10-Q and address these compliance issues, Nukkleus's common stock continues to trade on the Nasdaq Global Market. However, there is no guarantee the company will regain compliance within prescribed timeframes or receive additional extensions.
Nukkleus已收到来自纳斯达克的多份不合规通知,最新的一份于2024年8月22日发出,内容是未能提交2024年第二季度10-Q表格。该公司面临另外三个上市合规问题:每股交易价格低于1.00美元,公开持有股份的市场价值低于1500万美元,以及上市证券的市场价值低于5000万美元。该公司必须在2024年10月21日前向纳斯达克提交合规方案。如果被接受,纳斯达克可能会批准延期至2025年2月17日以恢复合规。针对买盘价格问题,该公司必须在2024年11月4日前解决,而市场价值要求必须在2024年11月12日前满足。在努力提交10-Q表格并解决这些合规问题的同时,Nukkleus的普通股仍在纳斯达克全球市场交易。然而,没有保证该公司将在规定的时间内恢复合规或获得额外的延期。
Nukkleus已收到来自纳斯达克的多份不合规通知,最新的一份于2024年8月22日发出,内容是未能提交2024年第二季度10-Q表格。该公司面临另外三个上市合规问题:每股交易价格低于1.00美元,公开持有股份的市场价值低于1500万美元,以及上市证券的市场价值低于5000万美元。该公司必须在2024年10月21日前向纳斯达克提交合规方案。如果被接受,纳斯达克可能会批准延期至2025年2月17日以恢复合规。针对买盘价格问题,该公司必须在2024年11月4日前解决,而市场价值要求必须在2024年11月12日前满足。在努力提交10-Q表格并解决这些合规问题的同时,Nukkleus的普通股仍在纳斯达克全球市场交易。然而,没有保证该公司将在规定的时间内恢复合规或获得额外的延期。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息